NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-05-274,285,714$1.40
$6.00MBuy
Ghiath M. SukhtianDirector2025-01-173,458,571$2.51
$8.68MBuy
Lawrence A. KenyonChief Financial Officer2024-09-265,000$5.69
$28.45kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian188.20%83,599,563$195.62MInsider
Faisal Ghiath Sukhtian125.81%55,884,786$130.77MInsider
Biolexis Pte Ltd57.28%25,443,159$59.54MInsider
Arun Kumar Pillai51.74%22,982,529$53.78MInsider
Pankaj Mohan18.65%8,285,115$19.39MInsider
Syntone Ventures LLC3.84%1,705,438$3.99MInsider
Schonfeld Strategic Advisors LLC3.07%1,364,809$3.19MInstitution
Vanguard Group Inc2.82%1,251,598$2.93MInstitution
Jeff Evanson1.82%808,459$1.89MInsider
Terry Dagnon1.47%653,058$1.53MInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK2.87%97.13%Net BuyingNet Buying
PLX8.02%91.98%Net BuyingNet Buying
CHRS47.70%18.07%Net SellingNet Selling
TARA48.27%51.73%Net Selling
IPA8.67%0.00%

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 13.36% institutional shareholders, 452.10% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 83.60M shares representing 188.20% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $231.57M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.